Yepez, Jose Cevallos |
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid |
|
|
| Completed | 3 | 610 | US | Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP | Chiesi Farmaceutici S.p.A. | Asthma | 06/24 | 06/24 | | |
| Active, not recruiting | 3 | 800 | Europe, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 05/24 | 05/25 | | |
| Active, not recruiting | 3 | 1667 | Japan, US | Remternetug (IV), LY3372993, Remternetug (SC), Placebo | Eli Lilly and Company | Alzheimer's Disease | 06/24 | 03/26 | | |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Active, not recruiting | 3 | 2196 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
Berner, Jason |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
| Recruiting | 3 | 14000 | Europe, Canada, US, RoW | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml | Novartis Pharmaceuticals | Primary Prevention of Atherosclerotic Cardiovascular Disease | 03/29 | 03/29 | | |
CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain |
|
|
| Recruiting | 2 | 384 | US | RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo | Reata, a wholly owned subsidiary of Biogen | Diabetic Peripheral Neuropathic Pain | 08/26 | 08/26 | | |
| Completed | N/A | 343 | US | Omnipod 5 Automated Glucose Control System | Insulet Corporation, Jaeb Center for Health Research | Type2 Diabetes | 03/24 | 03/24 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |